Last reviewed · How we verify
Basal cell carcinoma of skin — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Erivedge | vismodegib | Roche | Hedgehog Pathway Inhibitor [EPC] | Smoothened | 2012-01-01 | |
| Erismodegib | Erismodegib | Washington University School of Medicine | Smoothened homolog, Sonic hedgehog protein |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Roche · 1 drug in Basal cell carcinoma of skin
- Washington University School of Medicine · 1 drug in Basal cell carcinoma of skin
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Basal cell carcinoma of skin:
- Basal cell carcinoma of skin treatment updates — RSS
- Basal cell carcinoma of skin treatment updates — Atom
- Basal cell carcinoma of skin treatment updates — JSON
Cite this brief
Drug Landscape (2026). Basal cell carcinoma of skin — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/basal-cell-carcinoma-of-skin. Accessed 2026-06-11.
Related
- Basal cell carcinoma of skin full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing